SCHEMBL8254525

SCHEMBL8254525

CC(C)NC(=O)Cc1c(-c2ccccc2)ccn(Cc2ccccc2)c1=O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 1/20 0.44
▸ BRD4 O60885 3/20 0.43
▸ CNR2 P34972 1/20 0.43
▸ ALDH1A1 P00352 3/20 0.43
▸ POLB P06746 2/20 0.43
▸ MEN1 O00255 1/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ KDM4E B2RXH2 1/20 0.43
▸ BRD2 P25440 1/20 0.43
▸ BRD3 Q15059 1/20 0.43
▸ BRDT Q58F21 1/20 0.43
▸ EGLN1 Q9GZT9 4/20 0.42
▸ VEGFA P15692 1/20 0.42
▸ MAPK14 Q16539 1/20 0.41
▸ LMNA P02545 1/20 0.41
▸ HTT P42858 1/20 0.41
▸ DHPS P49366 1/20 0.41
▸ TP53 P04637 1/20 0.41
▸ HPGD P15428 1/20 0.40
▸ ELANE P08246 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8253863 0.72 ALDH1A1 (0.50) CNR2ALDH1A1POLBMEN1KMT2A
SCHEMBL12376651 0.70 BRD4 (0.73) SMN1; SMN2BRD4CNR2ALDH1A1POLB
SCHEMBL7674546 0.70 POLB (0.67) CNR2ALDH1A1POLBMEN1KMT2A
Hydrochloric Acid SCHEMBL27634849 0.69 POLB (0.65) CNR2ALDH1A1POLBMEN1KMT2A
SCHEMBL3175227 0.67 L3MBTL1 (0.59) SMN1; SMN2BRD4ALDH1A1POLBMEN1
SCHEMBL8253681 0.67 MAPT (0.50) BRD4ALDH1A1MEN1KMT2AKDM4E
SCHEMBL1137261 0.65 NOTUM (0.56) SMN1; SMN2BRD4CNR2POLBMEN1
SCHEMBL29354330 0.63 ALDH1A1 (0.67) SMN1; SMN2CNR2ALDH1A1POLBMEN1
SCHEMBL28069907 0.63 NOTUM (0.62) SMN1; SMN2BRD4CNR2ALDH1A1POLB
SCHEMBL12376644 0.63 BRD4 (0.57) SMN1; SMN2BRD4CNR2KDM4EBRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8350043-B2 Azinone and diazinone V3 inhibitors for depression and stress disorders PHARMACOPEIA, INC. (US) 2013-01-08 — — US disclosed
US-20070037822-A1 Azinone and diazinone V3 inhibitors for depression and stress disorders PHARMACOPEIA DRUG DISCOVERY, INC. (US) 2007-02-15 — — US disclosed
US-20070037822-A1 Azinone and diazinone V3 inhibitors for depression and stress disorders PHARMACOPEIA DRUG DISCOVERY, INC. (US) 2007-02-15 — — US disclosed
WO-2006133242-A2 AZINONE AND DIAZINONE V3 INHIBITORS FOR DEPRESSION AND STRESS DISORDERS PHARMACOPEIA, INC. (US) 2006-12-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070037822-A1 Azinone and diazinone V3 inhibitors for depression and stress disorders HTR3C, HTR3A, AZI2 SMN1; SMN2 4163/4885BRD4 713/4885CNR2 789/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback